• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    A Closer Look at 4 Analyst Recommendations For Elanco Animal Health

    7/1/24 8:01:11 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email

    During the last three months, 4 analysts shared their evaluations of Elanco Animal Health (NYSE:ELAN), revealing diverse outlooks from bullish to bearish.

    The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

    Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
    Total Ratings 0 2 2 0 0
    Last 30D 0 0 1 0 0
    1M Ago 0 1 0 0 0
    2M Ago 0 1 1 0 0
    3M Ago 0 0 0 0 0

    Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $19.75, with a high estimate of $23.00 and a low estimate of $16.00. Holding firm without variation, the current average remains at the previous average price target.

    price target chart

    Analyzing Analyst Ratings: A Detailed Breakdown

    A comprehensive examination of how financial experts perceive Elanco Animal Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

    Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
    David Westenberg Piper Sandler Lowers Neutral $16.00 $19.00
    Balaji Prasad Barclays Lowers Overweight $21.00 $23.00
    David Westenberg Piper Sandler Raises Neutral $19.00 $18.00
    Balaji Prasad Barclays Raises Overweight $23.00 $19.00

    Key Insights:

    • Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Elanco Animal Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.
    • Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Elanco Animal Health compared to the broader market.
    • Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Elanco Animal Health's stock. This comparison reveals trends in analysts' expectations over time.

    For valuable insights into Elanco Animal Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

    Stay up to date on Elanco Animal Health analyst ratings.

    Discovering Elanco Animal Health: A Closer Look

    Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production. The company's product portfolio of approximately 200 brands.

    Elanco Animal Health: Financial Performance Dissected

    Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

    Negative Revenue Trend: Examining Elanco Animal Health's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -4.14% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

    Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.66%, the company showcases strong profitability and effective cost control.

    Return on Equity (ROE): Elanco Animal Health's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.52% ROE, the company effectively utilizes shareholder equity capital.

    Return on Assets (ROA): Elanco Animal Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.23%, the company may face hurdles in achieving optimal financial returns.

    Debt Management: Elanco Animal Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.95.

    Analyst Ratings: What Are They?

    Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

    In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ELAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    1/22/2026Neutral → Overweight
    Piper Sandler
    12/9/2025$30.00Overweight
    Barclays
    11/21/2025$27.00Overweight
    KeyBanc Capital Markets
    11/19/2025$25.00Hold → Buy
    Argus
    10/7/2025$24.00Neutral → Overweight
    Analyst
    7/17/2025$18.00Market Perform → Outperform
    Leerink Partners
    6/26/2025Mkt Perform → Outperform
    William Blair
    12/9/2024$18.00Buy
    UBS
    More analyst ratings

    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $478,496 worth of shares (22,000 units at $21.75) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:41:24 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Modi Rajeev A. bought $95,985 worth of shares (4,500 units at $21.33), increasing direct ownership by 4% to 123,082 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:43:23 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elanco Animal Health upgraded by Piper Sandler

    Piper Sandler upgraded Elanco Animal Health from Neutral to Overweight

    1/22/26 8:20:23 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Elanco Animal Health with a new price target

    Barclays initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $30.00

    12/9/25 8:46:01 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KeyBanc Capital Markets initiated coverage on Elanco Animal Health with a new price target

    KeyBanc Capital Markets initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $27.00

    11/21/25 8:08:36 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results

    Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day OutlookFourth Quarter 2025 Financial Results:Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currencyReported Net Loss of $276 million, Adjusted Net Income of $64 millionAdjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7%Reported EPS of $(0.56), Adjusted EPS of $0.13Full Year 2025 Financial Results:Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025Revenue of $4,715 million, incre

    2/24/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco to Participate in Upcoming Investor Conferences

    INDIANAPOLIS, Ind., Feb. 19, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that management will participate in upcoming investor conferences. On Thursday, February 26, Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will participate in a fireside chat at the BofA 2026 Animal Health Summit at 11:35 a.m. ET.On Monday, March 2, Bob VanHimbergen, executive vice president and CFO, and Luke Smith, vice president and CFO – US Pet Health, US Farm Animal, and Global Manufacturing, will participate in a fireside

    2/19/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Announces Updates to Board of Directors

    INDIANAPOLIS, Feb. 13, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced updates to its Board of Directors. R. David Hoover and Deborah Kochevar will not stand for re-election at the conclusion of their terms at the 2026 Annual Meeting of Shareholders in May. Mr. Hoover is retiring from his role after joining the Board in September of 2018 as the first Chairman of the Board at the time of the company's IPO. Dr. Kochevar joined in March of 2019 as the company completed its separation from Eli Lilly and Company. "Dave Hoover's leadership was abso

    2/13/26 9:24:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Modi Rajeev A. covered exercise/tax liability with 4,392 shares, decreasing direct ownership by 3% to 155,901 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/5/26 4:21:53 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GC AND CORP SEC O'Neill Shiv covered exercise/tax liability with 4,738 shares, decreasing direct ownership by 5% to 83,834 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/5/26 4:19:14 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N covered exercise/tax liability with 37,898 units of Common Stock, decreasing direct ownership by 2% to 2,051,898 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/5/26 4:17:34 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    SEC Filings

    View All

    SEC Form 10-K filed by Elanco Animal Health Incorporated

    10-K - Elanco Animal Health Inc (0001739104) (Filer)

    2/24/26 9:19:48 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Elanco Animal Health Inc (0001739104) (Filer)

    2/24/26 6:28:19 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Elanco Animal Health Incorporated

    SCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/13/26 1:02:28 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Financials

    Live finance-specific insights

    View All

    Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results

    Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day OutlookFourth Quarter 2025 Financial Results:Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currencyReported Net Loss of $276 million, Adjusted Net Income of $64 millionAdjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7%Reported EPS of $(0.56), Adjusted EPS of $0.13Full Year 2025 Financial Results:Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025Revenue of $4,715 million, incre

    2/24/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement

    INDIANAPOLIS, Jan. 22, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. Eastern Standard Time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-

    1/22/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Investor Day Defines New Era as Sustainable Growth Company

    Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to <3x in 2027, with a long-term target of 2.0x to 2.5x.Expects innovation revenue contribution of approximately $1.1 billion in 2026, with aims to double revenue from 'Big 6' blockbuster potential products by 2028.Discusses 10+ major innovation products in development phase with 5-6 blockbuster-potential approvals expected between 2026 and 2031. Two in-house technology development platforms

    12/9/25 7:40:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    7/8/24 4:32:39 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/13/24 2:08:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/12/24 4:01:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Leadership Updates

    Live Leadership Updates

    View All

    Elanco executive appointed as Neurizon's Board Observer

    MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited ((ASX: NUZ &, NUZOA, OTCQB:NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE:ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative. The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. The appointment follo

    11/26/25 6:15:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    Banks
    Finance
    Savings Institutions
    Biotechnology: Pharmaceutical Preparations

    Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

    The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

    6/5/25 7:45:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care